I have read the article by Wakatsuki et al 1 with considerable interest. The study showed that the continuous oral treatment of postmenopausal women for 3 months with conjugated equine estrogens (CEE) (0.625 mg/day) alone or with medroxyprogesterone acetate (MPA) at the dose of 2.5 mg/day, significantly increased serum C-reactive protein (CRP) and amyloid A protein (SAA) levels. This effect was attenuated by the concurrent administration of MPA at the dose of 5 mg/day. CEE alone significantly decreased the concentration of E-selectin, but the concentrations of intracellular adhesion molecule (ICAM-1) and vascular cellular adhesion molecule (VCAM-1) did not change significantly. Concentrations of ICAM-1, VCAM-1, and E-selectin were all significantly reduced among postmenopausal women treated with CEE plus MPA 5 mg/day.
Response
Dr Rachoń pointed out that the antiinflammatory effect of medroxyprogesterone acetate (MPA) on plasma inflammatory markers, such as C-reactive protein and serum amyloid A protein, may not be related to the androgenic effect of MPA. Because MPA is a 17␣-hydroxyprogesterone derivative and binds progesterone and glucocorticoid receptors with a high affinity, we agree with his suggestion, in part, that its antiinflammatory properties may be attributed to its ability to interact with the progesterone and glucocorticoid receptors. According to Bentel et al, 1 however, MPA may also have an androgenic effect by activating androgen receptor-regulated pathways. In addition, Labrie et al 2 have demonstrated that the androgenic effect of MPA may have favorable effects in breast cancer subjects, comparable to other endocrine therapies, including tamoxifen. Therefore, MPA seems to have actions similar to those of testosterone derivatives. Testosterone derivatives have antiinflammatory effects and adverse effects on lipids and endothelial function.
We previously demonstrated that clinical doses of MPA may offset estrogen's favorable effects on high-density lipoprotein cholesterol and endothelial function in postmenopausal women. 3 In contrast, the addition of micronized progesterone, which has less androgenic effect than MPA, does not attenuate those favorable effects of estrogen. 4 The impact of MPA on these parameters may be related to its androgenic potency. Based on these findings, androgenic properties of MPA may be responsible for the reduction in plasma inflammatory markers. 5 Further studies are needed to determine the precise mechanism of the antiinflammatory effect of MPA.
